Referencias

1. Sampson CB. Adverse reactions and drug interactions with radiopharmaceuticals. Drug Safety 1993;8:280-94.
2. Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene diphosphonate – a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 1975;16:744-55.
3. Saha GB. Characteristics of specific radiopharmaceuticals. En: Fundamentals of Nuclear Pharmacy. Berlin: Springer, 2003. 5th Edition, p113.
4. Prospecto, marzo 2002. TechneScan® HDP Spain. Equipo para la preparación de una disolución inyectable de oxidronato de Tecnecio [99mTc]. Covidien Spain, S.L. C/ Fructuós Gelabert, 6 8ª planta. 08970 Sant Joan Despí. Barcelona.
5. Hesslewood SR, Keeling DH and Radiopharmacy Committee of the European Association of Nuclear Medicine. Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med Mol Imaging 1997;24:1179-82.
6. Real Decreto 1344/2007, de 11 de octubre, por el que se regula la farmacovigilancia de medicamentos de uso humano (Boletín Oficial del Estado nº 262 de 01-11-07, Madrid, España).
7. Balan KK, Choudhary AK, Balan A, Wishart G. Severe systemic reaction to 99mTc-methylene diphosphonate: a case report. J Nucl Med Technol 2003;31:76-8.
8. Elliott AT, Murray T, Mackie RM, Hunter JA. Severe reaction to diphosphonate: implications for treatment of Paget´s disease. BMJ 1988;297:592-3.
9. Spicer JA, Preston DF, Stephens RL. Adverse allergic reaction to technetium-99m methylene diphosphonate. J Nucl Med 1985;26:373-4.
10. Ramos-Gabatin A, Orzel JA, Maloney TR, Murnane JE, Borchert RD. Severe systemic reaction to diphosphonate bone imaging agents: skin testing to predict allergic response and a safe alternative agent. J Nucl Med 1986;27:1432-5.